Nordic Nanovector

338 articles with Nordic Nanovector

• Nordic Nanovector - Annual General Meeting Postponed

  3/31/2023

  The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.

• Nordic Nanovector - Annual and Remuneration Reports Approved

  3/23/2023

  On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2022.

• Nordic Nanovector ASA Results for the Second Half and Full Year 2022

  2/28/2023

  Nordic Nanovector ASA announces its results for the second half and full year 2022. A presentation by Nordic Nanovector's interim CEO & CFO, Ludvik Sandnes will be held in-person in Oslo and webcast live beginning at 8:30am CET - details below.

• Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast

  2/21/2023

  Nordic Nanovector ASA announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023.

• Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO)

  1/31/2023

  Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") announces that Ludvik Sandnes, former Chairperson of Nordic Nanovector, has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of the Company as from 1 February 2023.

• Nordic Nanovector ASA: Extraordinary General Meeting held - Jan 03, 2023

  1/3/2023

  An Extraordinary General Meeting of Nordic Nanovector ASA was held on 3 January 2023 in Oslo, Norway.

• Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023

  12/13/2022

  Nordic Nanovector ASA's largest shareholder North Energy ASA, that now holds 11,518,448 shares in the Company, has requested that the Board of Directors calls for an Extraordinary General Meeting in accordance with the Norwegian Public Limited Liability Companies Act §5-7.

• Nordic Nanovector update following shareholder vote against proposed merger with APIM Therapeutics

  12/9/2022

  Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed merger transaction with APIM Therapeutics AS ("APIM") did not obtain a sufficient majority of votes and was therefore voted down.

• Nordic Nanovector ASA: Extraordinary General Meeting held - December 1, 2022

  12/1/2022

  An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway.

• Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

  11/25/2022

  Nordic Nanovector ASA has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").

• Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics

  11/23/2022

  Nordic Nanovector ASA will host a webcast, including a question and answers session on Thursday, November 24 at 4.30 P.M. CET.

• Nordic Nanovector comment on Proposed Merger with APIM Therapeutics

  11/21/2022

  Nordic Nanovector ASA desires to share more information with the Company's shareholders about the proposed merger between the Company and APIM Therapeutics.

• Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting

  11/3/2022

  Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces the progress it has made in designing and developing a portfolio of novel and potent humanized anti-CD37 monoclonal antibodies with potential for treating B-cell malignancies or B-cell-driven autoimmune disorders.

• Nordic Nanovector consolidates Board to conserve resources while it explores strategic options

  9/15/2022

  Nordic Nanovector ASA announces that following the decisions to discontinue the PARADIGME study for its lead asset Betalutin®, restructure the company and appoint Carnegie Investment Bank to explore strategic options three members of the Company's Board have decided to step down.

• Nordic Nanovector ASA Results for the Second Quarter and First Half 2022

  8/31/2022

  Nordic Nanovector ASA announces its results for the second quarter and first half 2022.

• Nordic Nanovector consolidates senior leadership team and restructures to conserve resources as it explores strategic options

  8/26/2022

  Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that further to the decisions to discontinue the PARADIGME study for its lead asset Betalutin®, restructure the company and appoint Carnegie Investment Bank to explore strategic options the senior leadership team will be consolidated, and current Chief Executive Officer Erik Skullerud will transition out of his role.

• Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2022 Results Presentation Webcast

  8/24/2022

  Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second quarter and first half 2022 on Wednesday, 31 August 2022.

• Nordic Nanovector to explore strategic options

  8/18/2022

  Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that its Board of Directors (the "Board") has appointed Carnegie Investment Bank ("Carnegie") to explore strategic options available to the Company.

• Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin® in 3L R and R Follicular Lymphoma

  7/5/2022

  Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL).

• Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma

  6/21/2022

  Nordic Nanovector ASA (OSE: NANOV) today provides an update following its comprehensive review and independent data evaluation of PARADIGME, its ongoing Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).